Confidence In SpringWorks Grows With Expanded GSK Deal And Nirogacestat Plans
On Track For First Approval In 2023
SpringWork's lead drug is being studied in combination with no fewer than seven BCMA-targeting agents in multiple myeloma. • Source: Shutterstock 
